Navigation Links
Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

DALLAS, May 14 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it will make a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Jeffrey B. Davis, CEO of Access is scheduled to speak on Monday, May 19, 2008 at 3:10 pm local time, 9:10 am Eastern time and will give a corporate overview and discuss the Company's product opportunities.

The presentation will be available via a webcast and can be accessed at: http://www.wsw.com/webcast/rrshq13/accp.ob. The replay can be obtained at the same link for up to 90 days after the live presentation.

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hyp
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
2. Scientists call for more access to biotech crop data
3. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
4. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Study Finds Broadband Access Key to Empowerment of Minority Communities
7. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
8. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
9. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
11. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) announced today ... quarter and fiscal year 2009 on December 16, 2009, at ... at 4:45 p.m. ET Martek will conduct a conference call ... may listen to the call live via webcast by visiting ...
(Date:12/2/2009)... YORK, Dec. 2 Nearly 600 medical research executives, ... novel development approaches and innovative funding strategies at the ... FasterCures, the Washington-based center of the Milken ... multi-sector collaborations needed to turn a scientific discovery into ...
(Date:12/2/2009)... Holding NV,the Netherlands based biotechnology company focusing on protein ... that it,has appointed Wim E.M. Mol, Ph.D. as new ... Mol will be responsible for all of Pepscans corporate ... company. He brings to,Pepscan more than 20 years of ...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or ... leading pharmaceutical company,specializing in the development, manufacturing, and ... today announced that 105 of,its drugs have been ... was issued by China,s Ministry of Human Resources ...
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
... LAGUNA HILLS, Calif., Nov. 20 CalbaTech, Inc.,(OTC BB: ... concentrating on the collection and banking of adult stem ... platforms to,the biotech and pharmaceutical research markets and to ... U.S. Securities &,Exchange Commission that it anticipates to be ...
... GeneGo, Inc., the leading,provider of databases, software ... Utrecht University will be using MetaDrug in ... is designed for predicting,biological effects such as ... structures. Its content includes xenobiotics with known,activity, ...
... 20 /PRNewswire/ - Cytochroma Inc. announced today,that it ... trial of CTAP101,Capsules, the Company,s product candidate for ... disease (CKD). This Phase I/II clinical trial ... the pharmacokinetic profile and safety of CTAP101,Capsules in ...
Other Biology Technology:CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation 2Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease 2
(Date:12/3/2009)... Our ability to learn new information and adapt to changes ... memories, appears to lie in the minute junctions where nerve ... Medicine Center researchers. The study is published online this week ... led by Wen-Biao Gan, PhD, associate professor of physiology and ...
(Date:12/3/2009)... that staph infections are caused by many bacterial cells that ... called quorum sensing because many bacteria must be present to ... has determined that the very first stage of staph infection, ... occurs in a single cell and that this individual process ...
(Date:12/3/2009)... levels for the past three years in the troposphere ... Valladolid. The results, which are the first of their ... rose "significantly" between 2002 and 2005. , Over recent ... out about carbon dioxide (CO2) levels, and how these ...
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3CO2 levels rising in troposphere over rural areas 2OmniComm Systems Inc Retains Emerging Growth Equities Ltd as its Strategic Financial Advisor 51013 1OmniComm Systems Inc Retains Emerging Growth Equities Ltd as its Strategic Financial Advisor 51013 2OmniComm Systems Inc Retains Emerging Growth Equities Ltd as its Strategic Financial Advisor 51013 3A comprehensive review of addiction to prescription painkillers among patients and physicians 51008 1A comprehensive review of addiction to prescription painkillers among patients and physicians 51008 2A comprehensive review of addiction to prescription painkillers among patients and physicians 51008 3Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 1Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 3Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 4Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 5Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 6Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 7Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 8
... are some species of plants and animals favored by natural ... similarly? , According to a UC Riverside-led research team, the ... how fast a species consumes energy, per unit mass, ... largest number of species ever analyzed in a single study. ...
... Professor David Salt (Purdue University) and Tommy Sors ... been awarded First Place in the Interactive Media ... Science and Engineering Visualization Challenge. The winning ... the Genomics Digital Lab (GDL). , The ...
... simulation experts from Rhode Island Hospital discuss the ... appearing in the November 2008 issue of ... articles describe how simulation centers, along with new ... dynamic, complex and unanticipated medical situations in acute ...
Other Biology News:Ecologists say metabolism accounts for why natural selection favors only some species 2David Salt is 'worth his salt,' says Science magazine 2David Salt is 'worth his salt,' says Science magazine 3Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
XBP1 Antibody...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: